Skip to content

Study · Observational study · 2025

3 results

Association of tirzepatide with erectile dysfunction in people with type 2 diabetes.

Cowart K, Murphy C, Carris N

Journal of diabetes and its complications30 Jun 2025

PMID40614622 (opens in a new tab)DOI10.1016/j.jdiacomp.2025.109116 (opens in a new tab)PepBankPUB-40614622
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studySafety outcome

    In men with type 2 diabetes, tirzepatide was linked to lower erectile dysfunction or PDE-5 inhibitor use risk than sitagliptin, RR 0.70.

    In plain wordsIn men with diabetes, tirzepatide was linked to less erectile dysfunction or related drug use than sitagliptin.

    Peptide
    Tirzepatide
    Outcome
    DecreaseED diagnosis or PDE-5 inhibitor use versus sitagliptin
    Study

    n: not reported in source

    Comparator
    Sitagliptin
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    0.7 ratio
    tirzepatide versus sitagliptin
    95% confidence interval
    0.64 to 0.76 ratio
    tirzepatide versus sitagliptin

    Source sentences

    Summary
    Risk ratios (RR) for the composite outcome of ED diagnosis or PDE-5 inhibitor use were: tirzepatide vs. sitagliptin: RR, 0.70 (95 % CI: 0.64,0.76); tirzepatide vs. injectable semaglutide: RR, 0.67 (95 % CI: 0.62,0.72); tirzepatide vs. dulaglutide: RR, 0.55 (95 % CI: 0.51,0.59).
    4 context sentences
    Summary · context
    All comparisons were statistically significant (p < 0.001).
    Summary · context
    This retrospective cohort study used the TriNetX global health research network from May 13, 2022 to May 17, 2025.
    Summary · context
    Male patients aged 18-70 with T2D and no prior ED were included.
    Summary · context
    Three 1:1 propensity score-matched comparisons were conducted: tirzepatide vs. sitagliptin, injectable semaglutide, or dulaglutide.
  2. 02HumanObservational studySafety outcome

    In men with type 2 diabetes, tirzepatide was linked to lower erectile dysfunction or PDE-5 inhibitor use risk than injectable semaglutide, RR 0.67.

    In plain wordsIn men with diabetes, tirzepatide was linked to less erectile dysfunction or related drug use than injectable semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseED diagnosis or PDE-5 inhibitor use versus semaglutide
    Study

    n: not reported in source

    Comparator
    Injectable semaglutide
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    0.67 ratio
    tirzepatide versus injectable semaglutide
    95% confidence interval
    0.62 to 0.72 ratio
    tirzepatide versus injectable semaglutide

    Source sentences

    Summary
    Risk ratios (RR) for the composite outcome of ED diagnosis or PDE-5 inhibitor use were: tirzepatide vs. sitagliptin: RR, 0.70 (95 % CI: 0.64,0.76); tirzepatide vs. injectable semaglutide: RR, 0.67 (95 % CI: 0.62,0.72); tirzepatide vs. dulaglutide: RR, 0.55 (95 % CI: 0.51,0.59).
    4 context sentences
    Summary · context
    All comparisons were statistically significant (p < 0.001).
    Summary · context
    This retrospective cohort study used the TriNetX global health research network from May 13, 2022 to May 17, 2025.
    Summary · context
    Male patients aged 18-70 with T2D and no prior ED were included.
    Summary · context
    Three 1:1 propensity score-matched comparisons were conducted: tirzepatide vs. sitagliptin, injectable semaglutide, or dulaglutide.
  3. 03HumanObservational studySafety outcome

    In men with type 2 diabetes, tirzepatide was linked to lower erectile dysfunction or PDE-5 inhibitor use risk than dulaglutide, RR 0.55.

    In plain wordsIn men with diabetes, tirzepatide was linked to less erectile dysfunction or related drug use than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseED diagnosis or PDE-5 inhibitor use versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    0.55 ratio
    tirzepatide versus dulaglutide
    95% confidence interval
    0.51 to 0.59 ratio
    tirzepatide versus dulaglutide

    Source sentences

    Summary
    Risk ratios (RR) for the composite outcome of ED diagnosis or PDE-5 inhibitor use were: tirzepatide vs. sitagliptin: RR, 0.70 (95 % CI: 0.64,0.76); tirzepatide vs. injectable semaglutide: RR, 0.67 (95 % CI: 0.62,0.72); tirzepatide vs. dulaglutide: RR, 0.55 (95 % CI: 0.51,0.59).
    4 context sentences
    Summary · context
    All comparisons were statistically significant (p < 0.001).
    Summary · context
    This retrospective cohort study used the TriNetX global health research network from May 13, 2022 to May 17, 2025.
    Summary · context
    Male patients aged 18-70 with T2D and no prior ED were included.
    Summary · context
    Three 1:1 propensity score-matched comparisons were conducted: tirzepatide vs. sitagliptin, injectable semaglutide, or dulaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Versions 2 to 3

    21 Oct 2026, 18:59 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:07 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.